Arsenal Medical’s Foam Technology for Battlefield Injuries Receives $15.5 Million Phase II Defense Advanced Research Projects Agency Contract
12/10/2012 10:00:46 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Arsenal Medical, Inc. (Arsenal) today announced that it has been awarded a Phase II contract from the Defense Advanced Research Projects Agency (DARPA) to support continued development of its novel product to control intra-abdominal hemorrhage in soldiers injured on the battlefield. This Phase II award, for $15.5M, has resulted from Arsenal’s successful pre-clinical proof-of-concept work in Phase I of the project and is intended to support both late-stage development and regulatory submission. The Phase II award brings the total amount of money that Arsenal has received from DARPA for this program to $22.5M.